[The prognostic significance of cytologic differentiation grades of estrogen-treated prostata carcinoma. Progress control of 496 prostate carcinoma patients treated with estrogen for five years (author's transl)].
The morphologic differentiation grade of cytologic smear preparations proved to be a reliable gradation measurement for the prognosis of 496 patients suffering from prostate cancer and treated with estrogen. Compared with that of other cancer patients, the life expectancy of low-differentiated and anaplastic cancer patients undergoing estrogen treatment is so poor that the rationale of using antiandrogenous treatment in this carcinoma group seems extremely questionable to us. This is why, in view of the predictable prognosis, the differentiation grade of the tumor should be considered when undertaking therapeutic measures.